DSIP

📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.

What Is DSIP?

DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid linear neuropeptide first isolated by Schoenenberger and Monnier at the University of Basel in 1977. The peptide was identified by dialysing cerebral venous blood from rabbits during electrical stimulation of the intralaminar thalamus — a region known to drive delta-wave (slow-wave) sleep in the cortex — and concentrating the bioactive fraction. DSIP was named for the dominant electroencephalographic signature it produced when administered to recipient animals: increased proportion of delta-wave activity during sleep.

The well-characterised sequence is WAGGDASGE, molecular weight 848.81 Da, empirical formula C₃₅H₄₈N₁₀O₁₅. DSIP is structurally unusual among small CNS-active peptides — it is linear, unmodified at both termini, and contains no proline or cysteine residues. The peptide is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. DSIP is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The research-grade DSIP sold here is supplied uitsluitend voor laboratoriumonderzoek and is not intended for human or veterinary administration. For related circadian and sleep-axis peptide research, see our Epitalon en Selank product pages.

Mechanism of Action — Sleep Architecture, Stress Reactivity, and Neuroprotection

What makes DSIP unusual among research peptides is the breadth of effects documented for such a small, linear peptide without a clearly identified primary receptor. Published research has mapped its activity across three overlapping domains, each contributing to the observed phenotype:

• Sleep architecture modulation — delta-wave (slow-wave) sleep — DSIP increases the proportion of slow-wave (stage 3–4 / N3) sleep on quantitative EEG measurements in rodent, rabbit, and human research without proportionally reducing REM sleep. The effect is most pronounced when DSIP is administered to subjects with fragmented or shortened sleep, suggesting the peptide acts as a homeostatic sleep-pressure modulator rather than a primary sedative. Importantly, DSIP does not directly increase total sleep time in non-sleep-deprived subjects — it reorganises sleep architecture toward higher SWS proportion.
• HPA-axis and stress-reactivity modulation — Multiple published studies document attenuation of stress-induced cortisol and ACTH release in rodent restraint-stress models, alongside reduction of corticotropin-releasing hormone (CRH) signalling in the hypothalamus. The stress-buffering effect operates on a longer timescale than benzodiazepine sedatives and does not produce acute behavioural sedation, suggesting modulation of HPA-axis tone rather than acute anxiolysis.
• Anti-nociception, neuroprotection, and anti-withdrawal — DSIP shows analgesic effects in rodent thermal and chemical-nociception models, including opioid-naive subjects (suggesting non-opioid mechanism). Russian and Eastern European research has documented attenuation of opioid and alcohol withdrawal syndromes in preclinical models. Neuroprotective effects against oxidative stress, ischaemia, and excitotoxicity have been reported but remain mechanistically less well characterised than the sleep architecture work.

The receptor target for DSIP has not been definitively identified, which is unusual for a peptide with this much published behavioural data. Proposed mechanisms include GABA-A modulation, opioid-system crosstalk, and direct interaction with hypothalamic CRH neurons. The lack of an identified primary receptor combined with multiple documented effects suggests DSIP may act as a multimodal neuromodulator rather than a classical receptor agonist — a hypothesis that remains an active research question in published peptide pharmacology.

Published Research Applications

DSIP is used in laboratory research contexts that investigate:

• Sleep architecture and EEG research — quantitative EEG spectral analysis, slow-wave sleep proportion, sleep fragmentation in rodent and human research (Schoenenberger & Monnier, PNAS 1977; Kovalzon & Strekalova, Sleep Med Rev 2006)
• Stress reactivity and HPA-axis research — cortisol and ACTH dynamics, CRH expression, restraint-stress and chronic-mild-stress models in rodents
• Withdrawal syndrome research — opioid withdrawal severity, alcohol withdrawal, benzodiazepine taper; predominantly Russian and Eastern European published literature
• Nociception and chronic pain research — tail-flick, hot-plate, formalin, and chronic-constriction injury models in rodents; non-opioid mechanism characterisation
• Neuroprotection research — oxidative stress markers, ischaemia-reperfusion injury, excitotoxicity models
• Circadian biology research — entrainment, phase-shift response, melatonin and core-temperature rhythm modulation
• Comparative sleep-axis peptide research — benchmarking against Epitalon (pineal tetrapeptide) for circadian effects and against Selank for stress-buffering effects without sedation.

For broader context on where DSIP fits within the small CNS-active peptide landscape, see Epitalon (AEDG pineal tetrapeptide, circadian-axis research), Selank (heptapeptide anxiolytic), and Semax (heptapeptide nootropic). Browse the full onderzoekspeptiden catalogus voor gerelateerde verbindingen.

Beschikbare sterktes en concentraties

MedsBase stocks DSIP in three lyophilized vial sizes covering pilot dosing through extended research protocols. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:

All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection volume in rodent protocols or run extended studies from a single vial.

How It Compares — DSIP vs Epitalon

DSIP and Epitalon are the two most-cited small peptides involved in sleep, circadian, and rest-state research. They share several research-relevant features — both are short, linear, unmodified peptides without identified primary receptors, and both produce phenotypic effects that outlast plasma clearance — but their primary research signals are distinct: DSIP modulates sleep architecture directly via SWS proportion; Epitalon acts on the pineal-melatonin axis and circadian gene expression.

For sleep-architecture research, DSIP is the canonical first choice because it produces measurable EEG-level effects on slow-wave sleep proportion within a single sleep session. For circadian-rhythm and gene-regulatory research, Epitalon is preferred because the effect timescale matches the underlying biology (gene expression changes over days to weeks). The two are frequently co-administered when both axes are part of the research question.

Opslag en Reconstituering

Voor reconstituering: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized DSIP is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder. DSIP is hygroscopic — reseal vials promptly after opening and store in a desiccated container if available.

Reconstitueringsprocedure: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — 0.04 mL delivers a 100 mcg research dose. Swirl gently — do niet shake — and allow 2–5 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless.

Na reconstitutie: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration.

Veelgestelde vragen

What is DSIP used for in research?

DSIP is used in laboratory research investigating sleep architecture (particularly slow-wave sleep proportion), HPA-axis and stress reactivity, opioid and alcohol withdrawal syndromes, non-opioid analgesia, neuroprotection, and circadian biology. It is the most-cited sleep-axis research peptide that does not act primarily as a sedative — effects manifest as reorganisation of sleep architecture rather than increased total sleep time. The research-grade DSIP sold here is niet FDA-approved and is supplied strictly for laboratory research use only.

How is DSIP different from Epitalon?

Both are small unmodified peptides without identified primary receptors that influence rest-state biology, but their primary research signals differ. DSIP modulates sleep architecture at the EEG level — specifically increasing slow-wave sleep proportion within a single sleep session. Epitalon acts on the pineal-melatonin axis and circadian gene expression on a gene-expression timescale of days to weeks. The two are mechanistically complementary and frequently co-administered in research investigating combined sleep and circadian endpoints.

What is the typical DSIP research dose?

Published preclinical protocols typically use 100–500 mcg per administration in rodent models, given subcutaneously or intraperitoneally once daily for 7–28 day cycles. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — 0.04 mL equals 100 mcg.

Is DSIP FDA approved?

No. DSIP is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. All DSIP sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans or animals.

How should DSIP be stored?

Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. DSIP is hygroscopic — reseal vials promptly after opening. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade the peptide. Protect from direct light at all times.

How do I reconstitute DSIP?

Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 2–5 minutes for full dissolution. Do niet shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.

Welke sterktes heeft MedsBase op voorraad?

MedsBase carries DSIP in 5 mg, 10 mg, and 15 mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.

Does DSIP cause sedation in research models?

No — this is one of the most-cited findings in DSIP research. Unlike benzodiazepines or other classical sedatives, DSIP does not produce acute behavioural sedation, motor coordination loss, or impaired alertness. Instead it modulates sleep architecture toward a higher proportion of slow-wave sleep when the subject does sleep, without increasing total sleep time in non-sleep-deprived subjects. This distinct profile is one of the reasons DSIP has remained a research compound rather than a clinical sedative.

Can DSIP and Epitalon be stacked in research?

Yes. DSIP and Epitalon act on different timescales and biological compartments (acute EEG-level sleep architecture vs gene-expression-level circadian regulation), so co-administration is not pharmacologically redundant. Research protocols studying combined sleep-quality and circadian-rhythm endpoints frequently use both peptides.

Does DSIP cause side effects in research?

Published preclinical research has reported a notably clean safety profile at typical research doses, with no consistent sedation, motor-coordination effects, dependence liability, or rebound on discontinuation. Long-term human safety data is limited because the peptide has not undergone modern Western regulatory review. The small size and lack of identified primary receptor are consistent with the clean tolerability profile.

What is the half-life of DSIP?

In preclinical research, DSIP has a plasma half-life of approximately 7–15 minutes following intravenous or subcutaneous administration. The short plasma half-life is offset by the peptide’s ability to cross the blood-brain barrier and produce effects on sleep architecture and gene expression that persist well beyond plasma clearance.

Why was DSIP originally isolated?

DSIP was identified in 1977 by Schoenenberger and Monnier at the University of Basel by dialysing cerebral venous blood from rabbits during electrical stimulation of the intralaminar thalamus — a brain region known to drive delta-wave (slow-wave) sleep. They concentrated the bioactive fraction and characterised the peptide that produced the strongest sleep-EEG effect when transferred to recipient animals. The peptide was named for its dominant electroencephalographic signature: increased delta-wave activity during sleep.

How long does DSIP take to show effects in preclinical research?

Acute effects on sleep architecture and EEG delta-wave proportion are detectable within the first sleep session following administration. HPA-axis and stress-reactivity effects accumulate over 7–14 days of regular dosing. Anti-withdrawal effects in opioid and alcohol withdrawal models are typically measured over 3–7 day withdrawal periods.

Can I order DSIP for international shipping?

Yes. MedsBase ships DSIP worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy.

Other Peptides for Sleep, Circadian, and CNS Research

• Epitalon — AEDG pineal tetrapeptide — pineal-melatonin axis and circadian gene-expression research
• Selank — Anxiolytic heptapeptide tuftsin analog — GABA/BDNF stress-resilience research
• Semax — Russian-developed nootropic heptapeptide — melanocortin and dopaminergic modulation
• Oxytocine Acetaat — 9-aa cyclic nonapeptide — social-bonding and affiliative behavioural research
• BPC-157 — Body Protection Compound — healing and tissue-recovery research

Verder lezen

Meer opties in Peptiden

Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.

BPC-157

US$115.00 – US$705.00Prijsbereik: US$115.00 tot US$705.00

Retatrutide

US$310.00 – US$6,515.00Prijsbereik: US$310.00 tot US$6,515.00

BAC Water (Bacteriostatisch Water)

US$50.00 – US$150.00Prijsbereik: US$50.00 tot US$150.00

NAD⁺

US$210.00 – US$1,975.00Prijsbereik: US$210.00 tot US$1,975.00